We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

50 hedge funds and large institutions have $8.15M invested in Oramed Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

918% more call options, than puts

Call options by funds: $499K | Put options by funds: $49K

5.03% less ownership

Funds ownership: 10.72% → 5.69% (-5%)

12% less capital invested

Capital invested by funds: $9.3M → $8.15M (-$1.15M)

18% less funds holding

Funds holding: 61 → 50 (-11)

29% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 14

43% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 23

Holders
50
Holders Change
-11
Holders Change %
-18.03%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
10
Reduced
14
Closed
23
Calls
$499K
Puts
$49K
Net Calls
+$450K
Net Calls Change
+$217K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$528K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$235K
3
SRC
Samson Rock Capital
United Kingdom
+$118K
4
Squarepoint
Squarepoint
New York
+$110K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$102K

Top Sellers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
-$1.62M
2
Two Sigma Investments
Two Sigma Investments
New York
-$1.43M
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$815K
4
Morgan Stanley
Morgan Stanley
New York
-$771K
5
JP Morgan Chase
JP Morgan Chase
New York
-$386K
Name Holding Trade Value Shares
Change 		Change in
Stake
GJIA
26
Glass Jacobson Investment Advisors
Maryland
$43.9K +$39.3K +12,255 New
American Century Companies
27
American Century Companies
Missouri
$42.2K +$37.8K +11,789 New
Northern Trust
28
Northern Trust
Illinois
$41.4K – – –
CAM
29
Close Asset Management
United Kingdom
$41K +$8.02K +2,500 +28%
Prudential Financial
30
Prudential Financial
New Jersey
$40.1K +$35.9K +11,200 New
HighTower Advisors
31
HighTower Advisors
Illinois
$39K +$33.7K +10,500 New
TRCT
32
Tower Research Capital (TRC)
New York
$33.5K +$29.8K +9,310 +27,382%
UBS Group
33
UBS Group
Switzerland
$22K -$298K -92,992 -94%
Wells Fargo
34
Wells Fargo
California
$21.5K +$6.09K +1,901 +46%
Simplex Trading
35
Simplex Trading
Illinois
$21K +$19.5K +6,096 New
BCM
36
Bourgeon Capital Management
Connecticut
$20.1K – – –
EWM
37
Endurance Wealth Management
Rhode Island
$20K – – –
HNB
38
Huntington National Bank
Ohio
$17.9K -$160 -50 -1%
ME
39
McIlrath & Eck
Washington
$8.95K -$1.6K -500 -17%
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$6.55K +$5.87K +1,830 New
IA
41
IFP Advisors
Florida
$6.21K – – –
Northwestern Mutual Wealth Management
42
Northwestern Mutual Wealth Management
Wisconsin
$5.64K – – –
CHC
43
City Holding Co
West Virginia
$3.82K – – –
CFGS
44
Concourse Financial Group Securities
Alabama
$3.58K – – –
TWC
45
TD Waterhouse Canada
Ontario, Canada
$3.57K +$3.21K +1,000 New
NFSG
46
Newbridge Financial Services Group
Florida
$2.35K – – –
TSWM
47
Tyler-Stone Wealth Management
Ohio
$1K +$962 +300 New
BCMLT
48
Beacon Capital Management LLC (Tennessee)
Tennessee
$784 – – –
TF
49
TimeScale Financial
Massachusetts
$448 – – –
BBHC
50
Brown Brothers Harriman & Co
New York
$29 – – –
1
2
3

ORMP Hedge Fund Activity: Q2 2023 in Review

50 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2023, worth a combined $8.15M — down 12% from $9.3M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of ORMP and 13 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 10 added.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $528K. The largest seller was BML Capital Management, cutting an estimated $1.62M.

  • 50 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2023, down from 61 in Q1 2023.
  • Funds reported $8.15M of Oramed Pharmaceuticals stock for Q2 2023, down 12% quarter-over-quarter.
  • 13 funds opened new Oramed Pharmaceuticals positions in Q2 2023 and 23 closed out, a net change of -10 holders.
  • The largest Oramed Pharmaceuticals buyer in Q2 2023 was GSA Capital Partners, an estimated $528K added.
  • The largest Oramed Pharmaceuticals seller in Q2 2023 was BML Capital Management, an estimated $1.62M sold.

Based on aggregated 13F filings for Q2 2023.